Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development Programs
New York, USA, Lausanne, Switzerland and London, UK, 26 March 2012 ,
Celtic Therapeutics Management L.L.L.P. the global private equity firm focused on novel therapeutic product candidates, has announced a significant commitment to Antibody-Drug-Conjugate (“ADC”) products, with the launch of a new Switzerland-based company. ADC Therapeutics Sarl (“ADC Therapeutics”) has been formed with a pipeline of ten proprietary ADC oncology development programs, targeting multiple major cancers, inc…
read more »
Spirogen Ltd. announces a research collaboration and license agreement with Genentech for the discovery and development of antibody drug conjugates
London, UK,
Spirogen Ltd. ("Spirogen") a leading oncology-focused company developing DNA sequence targeted agents, announced a multi-year research collaboration and license agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:RHHBY).The two companies will collaborate on the discovery and development of antibody drug conjugates (ADCs) as potential anticancer agents, using Spirogen's proprietary PBD drugs and asso…
read more »
Commencement of a phase II clinical trial of SG2000 in ovarian cancer
London, UK, and New York, NY,
London, UK, and New York, NY, September 15, 2010 - Spirogen Limited (the "Company") and Celtic Therapeutics Holdings LP ("Celtic Therapeutics") announced today the commencement of a Phase II clinical trial of SG2000 in ovarian cancer. The trial is being sponsored by the National Cancer Institute (NCI) of the USA, and is now actively recruiting patients for treatment.The open-label Phase II study will evaluate th…
read more »
Celtic Therapeutics to invest up to $15m in the development of Spirogen's cancer drug SG2000
London, UK,
Spirogen Limited (Spirogen), the UK-based developer of DNA-interactive drugs, today announced that the private equity firm Celtic Therapeutics Holdings LP will invest up to $15 million in the development of Spirogen’s lead cancer drug, SG2000. Spirogen expects to continue clinical development of SG2000 in an upcoming National Cancer Institute-sponsored multi-centre Phase II study of SG2000 in the USA in resistant and refractory ovarian c…
read more »
The Results of the Phase I Studies of SG2000 (SJG-136) to be Presented at ASCO, Chicago, June 2008
Abstract ID: 2504 Abstract Title: Final results of Phase I and pharmacokinetic trial of SJG-136 administered on a daily x 3 schedule. Session Type: Oral Presentation Role: Presenter Igor Puzanov Date: Monday, June 02, 2008 Time: 8:00AM - 11:00AM Presentation Time: 8:30AM - 8:45AM -- ENDS -- Centanamycin has dual activity against malaria by Scott Baltic Last Updated: 2008-03-17 17:13…
read more »